OUR HISTORY
2021
-
Further expansion of operations in the Xerox Innovation Centre with access to additional infrastructure
-
Signed partnership with Antibe Therapeutics
-
First integrated Series B-stage program of Janpix goes IPO as part of Centessa Pharmaceuticals
2020
-
First integrated seed-stage program unlocks Series A funding – Dunad / Epidarex
-
Integrated the proteomics capabilities and drug development team
-
Dalriada welcomes its 50th employee
-
Adding >200 years of drug discovery expertise through significant expansion of the senior scientific team
-
First integrated Series A-Stage program unlocks Series B funding – Janpix / Medicxi
2019
-
Signed a partnership with Canopy Growth to create and advance an NCE pipeline
-
Expanded operations into 12,500 sf lab site in the GTA
2017
-
Founded in the Toronto area, a key North American life-sciences research hub
-
11-people team of med chemists, in vitro biologists, biochemists and adme to support a Medicxi-funded integrated biotech program
OUR CLIENTS
“Since its inception Janpix has been working with Dalriada. Their expertise and devotion has contributed significantly to the success of our STAT degrader platform and our being able to secure additional financing to further advance the project. Dalriada continues to play an important role in our drug discovery efforts with their team considered an extension of our own and our enjoying a hand-in-glove relationship.”
Dr. R. Fleck, Chief Executive Officer
"Dalriada’s expert biology team rapidly designed and delivered a bespoke novel primary cell assay system, with multiple inflammatory readouts, that allowed us to effectively screen several candidate compounds and significantly advance our target validation efforts towards our development of next generation therapies in skin diseases."
Dr. T. Sparey, Chief Executive Officer
“We partnered with Dalriada to help us expand our footprint in the medical cannabis field using a pharmaceutical approach and mindset. The team at Dalriada far exceeded our expectations by rapidly establishing a drug discovery platform, delivering a substantive IP portfolio and robust pipeline of several distinct classes of novel proprietary cannabinoid analogs which are progressing into preclinical development.”
Dr. M. Ware, Chief Medical Officer
